Boison Detlev
Legacy Research, R.S. Dow Neurobiology Laboratories, 1225 NE 2nd Avenue, Portland, OR 97232, USA.
Curr Opin Pharmacol. 2008 Feb;8(1):2-7. doi: 10.1016/j.coph.2007.09.002. Epub 2007 Oct 17.
Adenosine is a modulator of brain function uniquely positioned to integrate excitatory and inhibitory neurotransmission. The past few years brought a wealth of new data fostering our understanding of how the adenosine system is involved in the pathogenesis of neurological diseases. Thus, dysregulation of the adenosine system is implicated in epileptogenesis and cell therapies have been developed to locally augment adenosine in an approach to prevent seizures. While activation of inhibitory adenosine A(1) receptors is beneficial in epilepsy, chronic pain and cerebral ischemia, inhibition of facilitatory A(2A) receptors has profound neuroprotective effects, which are currently exploited in clinical trials in Parkinson's disease. A new era of adenosine-based therapies has begun, with the prospect to cover a wide range of neurological diseases.
腺苷是一种脑功能调节剂,在整合兴奋性和抑制性神经传递方面具有独特地位。过去几年涌现了大量新数据,增进了我们对腺苷系统如何参与神经疾病发病机制的理解。因此,腺苷系统失调与癫痫发生有关,并且已经开发了细胞疗法来局部增强腺苷以预防癫痫发作。虽然抑制性腺苷A(1)受体的激活在癫痫、慢性疼痛和脑缺血中有益,但促进性A(2A)受体的抑制具有深远的神经保护作用,目前正在帕金森病的临床试验中得到应用。基于腺苷的治疗新时代已经开启,有望涵盖广泛的神经疾病。